{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:09:22Z","timestamp":1792526962515,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.trecan.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:04:57Z","timestamp":1778040297000},"page":"584-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Repurposing payloads: next generation of antibody\u2013drug conjugates"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5737-1609","authenticated-orcid":false,"given":"Katherine","family":"Shatzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-2948","authenticated-orcid":false,"given":"Florian L.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.04.001_bb0005","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/pharmaceutics15082160","article-title":"Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload","volume":"15","author":"Kondrashov","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.trecan.2026.04.001_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u2018biological missile\u2019 for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antras","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.trecan.2026.04.001_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0035","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-3321","article-title":"Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer","author":"Rampa","year":"2026","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.trecan.2026.04.001_bb0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/08830185.2025.2545364","article-title":"Antibody-drug conjugates in breast cancer: from therapeutic and immune activation mechanisms to resistance prevention","volume":"44","author":"Nik Amirah Auni","year":"2025","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0045","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.001_bb0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.trecan.2026.04.001_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0060","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241309461","article-title":"Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0070","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.001_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.001_bb0080","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","article-title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","volume":"31","author":"Yver","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0085","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcph.2295","article-title":"Trastuzumab deruxtecan dosing in human epidermal growth factor receptor 2-positive gastric cancer: population pharmacokinetic modeling and exposure-response analysis","volume":"63","author":"Yoshihara","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0095","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.001_bb0100","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1158\/1078-0432.CCR-21-1560","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors","volume":"27","author":"Takahashi","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.001_bb0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.04.001_bb0110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.trecan.2026.04.001_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105019","article-title":"Trastuzumab deruxtecan: redefining precision oncology across HER2-driven cancers","volume":"217","author":"Jalali","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0120","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.7150\/jca.86746","article-title":"Adverse event profile differences between trastuzumab emtansine and trastuzumab deruxtecan: a real-world, pharmacovigilance study","volume":"14","author":"Liu","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0130","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cortes","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.04.001_bb0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/cancers16020447","article-title":"Antibody-drug conjugates: the dynamic evolution from conventional to next-generation constructs","volume":"16","author":"Metrangolo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.001_bb0140","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0145","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-22-0804","article-title":"Use of payload binding selectivity enhancers to improve therapeutic index of maytansinoid-antibody-drug conjugates","volume":"22","author":"Nguyen","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0150","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.001_bb0155","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.23.02044","article-title":"Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: a global phase I trial","volume":"42","author":"Yao","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0160","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.001_bb0165","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0170","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0175","series-title":"KADCYLA\u2122 (Ado-Trastuzumab Emtansine) for Injection, for Intravenous Use Initial US Approval 2013","author":"Drug, US FDA","year":"2013"},{"key":"10.1016\/j.trecan.2026.04.001_bb0180","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.24.00529","article-title":"Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)","volume":"43","author":"Turner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0185","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.trecan.2026.04.001_bb0190","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0195","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.3390\/ijms26136523","article-title":"Antibody-drug conjugates powered by deruxtecan: innovations and challenges in oncology","volume":"26","author":"Jang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2026.04.001_bb0200","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.001_bb0205","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1699768","article-title":"Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human phase 1 studies","volume":"12","author":"Li","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.trecan.2026.04.001_bb0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40135-024-00322-5","article-title":"Incidence and mitigation of corneal pseudomicrocysts induced by antibody-drug conjugates (ADCs)","volume":"12","author":"Lindgren","year":"2024","journal-title":"Curr. Ophthalmol. Rep."},{"key":"10.1016\/j.trecan.2026.04.001_bb0215","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41698-025-01131-0","article-title":"The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer","volume":"9","author":"Lin","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0220","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.trecan.2026.04.001_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122285","article-title":"Preparation of an ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy","volume":"301","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.trecan.2026.04.001_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.12793\/tcp.2025.33.e21","article-title":"A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025","volume":"33","author":"Koo","year":"2025","journal-title":"Transl. Clin. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0235","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.trecan.2026.04.001_bb0240","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.tips.2021.07.005","article-title":"Key metrics to expanding the pipeline of successful antibody-drug conjugates","volume":"42","author":"Nessler","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.trecan.2026.04.001_bb0245","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10555-024-10231-5","article-title":"Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: a systematic review and meta-analysis","volume":"44","author":"Tang","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.trecan.2026.04.001_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.969183","article-title":"The microtubule cytoskeleton: an old validated target for novel therapeutic drugs","volume":"13","author":"Lafanechere","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102922","article-title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","volume":"135","author":"Geraud","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2026.04.001_bb0265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neo.2020.12.001","article-title":"Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping","volume":"23","author":"Khera","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.trecan.2026.04.001_bb0270","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","article-title":"Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned","volume":"16","author":"Lopez de Sa","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0275","article-title":"Key considerations based on pharmacokinetic\/pharmacodynamic in the design of antibody-drug conjugates","volume":"14","author":"Gao","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0280","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/00498254.2024.2351044","article-title":"Translational PK\/PD framework for antibody-drug conjugates to inform drug discovery and development","volume":"54","author":"Liao","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.trecan.2026.04.001_bb0285","first-page":"124","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0290","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/cancers18010005","article-title":"Pharmacokinetic and pharmacodynamic modeling of antibody-drug conjugates","volume":"18","author":"Glassman","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.001_bb0295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10928-024-09956-1","article-title":"QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life","volume":"52","author":"Khera","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.trecan.2026.04.001_bb0300","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1208\/s12248-016-9892-3","article-title":"Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design","volume":"18","author":"Maass","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.trecan.2026.04.001_bb0305","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.xphs.2019.01.034","article-title":"A \u201cdual\u201d cell-level systems PK-PD model to characterize the bystander effect of ADC","volume":"108","author":"Singh","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.trecan.2026.04.001_bb0310","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10928-023-09884-6","article-title":"Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)","volume":"51","author":"Scheuher","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.trecan.2026.04.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251324889","article-title":"Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer","volume":"17","author":"Kang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0320","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.04.001_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/ijch.202300042","article-title":"Probing the internalization and efficacy of antibody-drug conjugate via site-specific Fc-glycan labelling of a homogeneous antibody targeting SSEA-4 bearing tumors","volume":"63","author":"Shivatare","year":"2023","journal-title":"Isr. J. Chem."},{"key":"10.1016\/j.trecan.2026.04.001_bb0330","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302058","article-title":"A novel antifolate suppresses growth of FPGS-deficient cells and overcomes methotrexate resistance","volume":"6","author":"van der Krift","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.trecan.2026.04.001_bb0335","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200032","article-title":"A patent review on FDA-approved antibody-drug conjugates, their linkers and drug payloads","volume":"17","author":"Chia","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.trecan.2026.04.001_bb0345","series-title":"Research and Development Pipeline","author":"Daiichi Sankyo Co., L.","year":"2025"},{"key":"10.1016\/j.trecan.2026.04.001_bb0350","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.001_bb0355","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.trecan.2026.04.001_bb0360","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1538-7445.AM2024-2051","article-title":"Innovations in ADC technology platform with legumain-cleavable KSP-inhibitor payloads adaptable to various aspects of cancer biology","volume":"84","author":"Lerchen","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.001_bb0365","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10637-015-0211-0","article-title":"First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors","volume":"33","author":"LoRusso","year":"2015","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.04.001_bb0370","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.3390\/cancers12113464","article-title":"IL3RA-targeting antibody-drug conjugate BAY-943 with a kinesin spindle protein inhibitor payload shows efficacy in preclinical models of hematologic malignancies","volume":"12","author":"Kirchhoff","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.001_bb0375","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.trecan.2020.05.010","article-title":"Why great mitotic inhibitors make poor cancer drugs","volume":"6","author":"Yan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0380","series-title":"Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates","author":"Vincerx Pharma, INC","year":"2024"},{"key":"10.1016\/j.trecan.2026.04.001_bb0385","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.04.001_bb0390","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2022-168936","article-title":"ORM-6151: a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for AML","volume":"140","author":"Palacino","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.04.001_bb0395","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.04.001_bb0400","first-page":"27","article-title":"Edotecarin: a novel topoisomerase I inhibitor","volume":"5","author":"Saif","year":"2005","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0405","first-page":"305","article-title":"Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report","volume":"47","author":"Vrdoljak","year":"2006","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.trecan.2026.04.001_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.914342","article-title":"Trabectedin and lurbinectedin: mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma","volume":"12","author":"Gadducci","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108598","article-title":"Lurbinectedin for extensive stage\u2014small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes","volume":"205","author":"Krayim","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0420","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2025.43.16_suppl.8006","article-title":"Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial","volume":"43","author":"Paz-Ares","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0425","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-005-0149-6","article-title":"Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors","volume":"58","author":"Yamada","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0430","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF01053939","article-title":"Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies. A Southwest Oncology Group study","volume":"15","author":"Taylor","year":"1993","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0435","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00000421-199008000-00006","article-title":"Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the gynecologic oncology group","volume":"13","author":"Muss","year":"1990","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0440","series-title":"Her2-PM160057P a New Antibody Drug Conjugate","author":"PharmaMar","year":"2018"},{"key":"10.1016\/j.trecan.2026.04.001_bb0445","doi-asserted-by":"crossref","first-page":"7980","DOI":"10.1038\/s41598-023-34437-9","article-title":"Structural and functional analyses of the echinomycin resistance conferring protein Ecm16 from Streptomyces lasalocidi","volume":"13","author":"Gade","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.04.001_bb0450","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/acs.bioconjchem.8b00843","article-title":"Natural product bis-intercalator depsipeptides as a new class of payloads for antibody-drug conjugates","volume":"30","author":"Ratnayake","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.trecan.2026.04.001_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113259","article-title":"Pooled safety analysis of single-agent lurbinectedin in patients with advanced solid tumours","volume":"192","author":"Leary","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.001_bb0460","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","article-title":"Nucleoside analogues and nucleobases in cancer treatment","volume":"3","author":"Galmarini","year":"2002","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0465","article-title":"Overview of biologically active nucleoside phosphonates","volume":"8","author":"Groaz","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.trecan.2026.04.001_bb0470","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1074\/jbc.273.34.21966","article-title":"Incorporation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro","volume":"273","author":"Kramata","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2026.04.001_bb0475","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000292582","article-title":"Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo","volume":"56","author":"Valiaeva","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.trecan.2026.04.001_bb0480","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10245330601027316","article-title":"Troxacitabine in leukemia","volume":"11","author":"Swords","year":"2006","journal-title":"Hematology"},{"key":"10.1016\/j.trecan.2026.04.001_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.889737","article-title":"Phosphonates and phosphonate prodrugs in medicinal chemistry: past successes and future prospects","volume":"10","author":"Krecmerova","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.trecan.2026.04.001_bb0490","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/jm00123a010","article-title":"Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position","volume":"32","author":"Marsham","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.04.001_bb0495","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11912-003-0098-3","article-title":"Novel antifolate drugs","volume":"5","author":"Purcell","year":"2003","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.trecan.2026.04.001_bb0500","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.hoc.2012.02.002","article-title":"The antifolates","volume":"26","author":"Visentin","year":"2012","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.trecan.2026.04.001_bb0505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10637-005-4541-1","article-title":"From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates","volume":"24","author":"Walling","year":"2006","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.04.001_bb0510","first-page":"1479","article-title":"Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement","volume":"1","author":"Wedge","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.001_bb0515","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.001_bb0520","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-19-0419","article-title":"The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination-deficient and Schlafen 11-positive cancer cells and synergize with olaparib","volume":"25","author":"Marzi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.001_bb0525","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00280-025-04778-5","article-title":"Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas","volume":"95","author":"O\u2019Sullivan Coyne","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.001_bb0530","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/acsptsci.9b00056","article-title":"Freedom of Information Act access to an investigational new drug application","volume":"2","author":"Southall","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.trecan.2026.04.001_bb0535","series-title":"Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary","year":"2010"},{"key":"10.1016\/j.trecan.2026.04.001_bb0540","first-page":"1509","article-title":"Patents, partnerships, and the pre-competitive collaboration myth in pharmaceutical innovation","volume":"48","author":"Vertinsky","year":"2014","journal-title":"UCDL Rev."},{"key":"10.1016\/j.trecan.2026.04.001_bb0545","first-page":"297","article-title":"Cancer\u2019s IP","volume":"96","author":"Sherkow","year":"2018","journal-title":"NCL Rev."},{"key":"10.1016\/j.trecan.2026.04.001_bb0550","series-title":"An Ethical Option for Shelved Drugs","author":"Bakker","year":"2022"},{"key":"10.1016\/j.trecan.2026.04.001_bb0555","article-title":"Creating a Nonprofit Marketplace for Shelved Drugs: Lessons from a Pilot Project","author":"Choe","year":"2012"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:21:43Z","timestamp":1784042503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326000762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2405803326000762"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.04.001","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing payloads: next generation of antibody\u2013drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}